Investigation of serum proteome alterations in human glioblastoma multiforme

Glioblastoma multiforme (GBM) or grade IV astrocytoma is the most common and lethal adult malignant brain tumor. The present study was conducted to investigate the alterations in the serum proteome in GBM patients compared to healthy controls. Comparative proteomic analysis was performed employing classical 2DE and 2D‐DIGE combined with MALDI TOF/TOF MS and results were further validated through Western blotting and immunoturbidimetric assay. Comparison of the serum proteome of GBM and healthy subjects revealed 55 differentially expressed and statistically significant (p <0.05) protein spots. Among the identified proteins, haptoglobin, plasminogen precursor, apolipoprotein A‐1 and M, and transthyretin are very significant due to their functional consequences in glioma tumor growth and migration, and could further be studied as glioma biomarkers and grade‐specific protein signatures. Analysis of the lipoprotein pattern indicated elevated serum levels of cholesterol, triacylglycerol, and low‐density lipoproteins in GBM patients. Functional pathway analysis was performed using multiple software including ingenuity pathway analysis (IPA), protein analysis through evolutionary relationships (PANTHER), database for annotation, visualization and integrated discovery (DAVID), and GeneSpring to investigate the biological context of the identified proteins, which revealed the association of candidate proteins in a few essential physiological pathways such as intrinsic prothrombin activation pathway, plasminogen activating cascade, coagulation system, glioma invasiveness signaling, and PI3K signaling in B lymphocytes. A subset of the differentially expressed proteins was applied to build statistical sample class prediction models for discrimination of GBM patients and healthy controls employing partial least squares discriminant analysis (PLS‐DA) and other machine learning methods such as support vector machine (SVM), Decision Tree and Naïve Bayes, and excellent discrimination between GBM and control groups was accomplished.

[1]  M. Schuhmann,et al.  Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  G. Reifenberger,et al.  The WHO Classification of Tumors of the Nervous System , 2002, Journal of neuropathology and experimental neurology.

[3]  Anushya Muruganujan,et al.  Applications for protein sequence–function evolution data: mRNA/protein expression analysis and coding SNP scoring tools , 2006, Nucleic Acids Res..

[4]  A. Kandutsch,et al.  The role of cholesterol in malignancy. , 1978, Progress in experimental tumor research.

[5]  Vani Santosh,et al.  Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. , 2010, Journal of proteome research.

[6]  L. Deangelis,et al.  Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas , 2011, Journal of Neuro-Oncology.

[7]  H. Ginsberg,et al.  Hypocholesterolemia and acute myelogenous leukemia: Association between disease activity and plasma low‐density lipoprotein cholesterol concentrations , 1986, Cancer.

[8]  J. Bertolini,et al.  Therapeutic potential of vitamin D-binding protein. , 2004, Trends in biotechnology.

[9]  B. Efron,et al.  The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy , 1975, Cancer.

[10]  N. Tsopanoglou,et al.  On the mechanism(s) of thrombin induced angiogenesis. , 2000, Advances in experimental medicine and biology.

[11]  James P Basilion,et al.  A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. , 2010, Neoplasia.

[12]  B. Mittal,et al.  High resolution NMR based analysis of serum lipids in Duchenne muscular dystrophy patients and its possible diagnostic significance , 2010, NMR in Biomedicine.

[13]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[14]  Harish Srinivasan,et al.  Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[15]  A. Kaye,et al.  The role of the plasminogen activation cascade in glioma cell invasion: a review , 2003, Journal of Clinical Neuroscience.

[16]  M. Kiechle,et al.  Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. , 2002, Clinical breast cancer.

[17]  A. Sotgiu,et al.  Lipid Metabolism Impairment in Human Gliomas: Expression of Peroxisomal Proteins in Human Gliomas at Different Grades of Malignancy , 2010, International journal of immunopathology and pharmacology.

[18]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[19]  U. Fischer,et al.  Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol , 2005, Clinical Cancer Research.

[20]  P. Grieb,et al.  Serum Cholesterol in Cerebral Malignancies , 2004, Journal of Neuro-Oncology.

[21]  A. Kyritsis,et al.  Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy , 2010, Journal of Neuroimmunology.

[22]  N. Gogtay,et al.  Serum proteome analysis of vivax malaria: An insight into the disease pathogenesis and host immune response. , 2012, Journal of proteomics.

[23]  R. Fimmers,et al.  Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.

[24]  J. Chang-Claude,et al.  The Gc2 Allele of the Vitamin D Binding Protein Is Associated with a Decreased Postmenopausal Breast Cancer Risk, Independent of the Vitamin D Status , 2008, Cancer Epidemiology Biomarkers & Prevention.

[25]  F. Howe,et al.  Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. , 2008, Clinical chemistry.

[26]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.

[27]  S. Cha CNS Tumors: Monitoring Therapeutic Response and Outcome Prediction , 2006, Topics in magnetic resonance imaging : TMRI.

[28]  A. Basdevant Steroids and lipid metabolism: mechanism of action. , 1992, International journal of fertility.

[29]  L. Deangelis,et al.  YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.

[30]  H. Steinmetz,et al.  Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[31]  Sanjeeva Srivastava,et al.  Proteomic technologies for the identification of disease biomarkers in serum: Advances and challenges ahead , 2011, Proteomics.

[32]  C. Ríos,et al.  Plasma Ceruloplasmin Ferroxidase Activity Correlates with the Nigral Sonographic Area in Parkinson’s Disease Patients: A Pilot Study , 2011, Neurochemical Research.

[33]  S. Pradhan,et al.  In vitro, high‐resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view , 2009, NMR in biomedicine.

[34]  J. Weiss,et al.  Serum acute-phase proteins and immunoglobulins in patients with gliomas. , 1979, Cancer research.

[35]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[36]  Jean-Pierre Julien,et al.  Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.

[37]  T. Schallert,et al.  The role of thrombin in gliomas , 2005, Journal of thrombosis and haemostasis : JTH.

[38]  L. Turecký,et al.  Serum ceruloplasmin and copper levels in patients with primary brain tumors , 1984, Klinische Wochenschrift.

[39]  S. Niclou,et al.  Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.

[40]  S. Brem,et al.  Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. , 1998, Journal of neurosurgery.

[41]  G. Butti,et al.  Vitamin D Metabolites Activate the Sphingomyelin Pathway and Induce Death of Glioblastoma Cells , 1998, Acta Neurochirurgica.

[42]  Jean Mosser,et al.  Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach , 2011, Proteome Science.

[43]  M. Shibuya Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor , 2009, The FEBS journal.

[44]  Douglas S Rehder,et al.  Glycosylation status of vitamin D binding protein in cancer patients , 2009, Protein science : a publication of the Protein Society.

[45]  J. Gurney,et al.  Brain and other central nervous system tumors: rates, trends, and epidemiology , 2001, Current opinion in oncology.

[46]  A. Avgerinos,et al.  Serum lipids and lipoprotein disorders in cancer patients , 1987, Cancer.

[47]  Paul S Mischel,et al.  Molecular Analysis of Glioblastoma: Pathway Profiling and Its Implications for Patient Therapy , 2003, Cancer biology & therapy.

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  H. Hasan,et al.  Study of Lipoproteins in Patients with Brain Tumors , 2009 .

[50]  K. Somasundaram,et al.  Serum proteomics of glioma: methods and applications , 2009, Expert review of molecular diagnostics.

[51]  P. Kleihues,et al.  Molecular pathogenesis of astrocytic tumours , 2004, Journal of Neuro-Oncology.